Early results from the Phase 3 clinical trial of the hepciden mimetic ‘rusfertide’ have recently been published.

Rusfertide aims to overcome the need for phlebotomy in patients with polycythemia vera (PV), by keeping haematocrit below .45.

Early phase 3 trial results show that rusfertide was well tolerated and effective in keeping PV patients’ haematocrit below .45.

These results are extremely promising for PV patients.

The linked article provides more detail, including commentary from Australia’s Dr Cavan Bennett from the Walter and Eliza Hall Institute  HERE.